

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-201) NEMVALEUKIN ALFA

PRONUNCIATION nem" va loo' kin al' fa

THERAPEUTIC CLAIM Treatment of metastatic solid malignancies

CHEMICAL NAMES

1. 75-133-Interleukin 2 [125-serine] (human) fusion protein with peptide linker (GG) fusion protein with 4-74-interleukin 2 (human) fusion protein with peptide linker (GSGGGS) fusion protein with 1-165-interleukin 2 receptor α -chain (human)(Source: CAS)
2. human interleukin 2 fragment (1-59), variant (Cys¹²⁵>Ser⁵¹), fused via peptidyl linker (⁶⁰GG⁶¹) to human interleukin 2 fragment (62-132), fused via peptidyl linker (¹³³GSGGGS¹³⁸) to human interleukin 2 receptor α -chain fragment (139-303), produced in Chinese hamster ovary (CHO) cells, glycosylated; human interleukin 2 (IL-2) (75-133)-peptide [Cys¹²⁵⁽⁵¹⁾>Ser]-mutant (1-59), fused via a G₂ peptide linker (60-61) to human interleukin 2 (IL-2) (4-74)- peptide (62-132) and via a GSG₃S peptide linker (133- 138) to human interleukin 2 receptor α -chain (IL2R subunit alpha, IL2R α , IL2RA) (1-165)-peptide (139- 303), produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source : WHO pINN list 123)

STRUCTURAL FORMULA

Sequence

SKNFHLRPRD	LISNINVIVL	ELKGSETTFM	CEYADETATI	VEFLNRWITF	50
SQSIISTLTG	GSSSTKKTQL	QLEHLLLDLQ	MILNGINNYK	NPKLTRMLTF	100
KFYMPKKATE	LKHLQCLEEE	LKPLEEVLNL	AQSGGGGSEL	CDDDPPEIPH	150
ATFKAMAYKE	GTMLNCECKR	GFRRIKSGSL	YMLCTGNSSH	SSWDNQCQCT	200
SSATRNTTKQ	VTPQPEEQKE	RKTTEMQSPM	QPVDQASLPG	HCREPPPWEN	250
EATERIYHFV	VGQMVYYQCV	QGYRALHRGP	AESVCKMTHG	KTRWTQPQLI	300
CTG					350

Disulfide bridges

31-116	141-285	184-242	269-301	166-197	168-199
--------	---------	---------	---------	---------	---------

Glycosylation sites

N187	N206	T212
------	------	------

MOLECULAR FORMULA C₁₅₀₁H₂₃₇₈N₄₂₀O₄₆₁S₂₃

MOLECULAR WEIGHT 34.4 kDa

TRADEMARKS None yet

SPONSOR Alkermes, Inc.

CODE DESIGNATIONS ALKS 4230, RDB-1450

CAS REGISTRY NUMBER 2315268-27-8

UNII

7ZX1Q9SJ1F

WHO NUMBER

11402

SCS